SEL1L and pancreatic neoplasm: We classified pancreatic cancer patients into subgroups based on age (<45 or >45), sex (male or female), grade (G1, 2, 3, or 4), T stage (T1/2 or T3/4), N staging (N0 or N1), M stage (M0 or M1), clinical stage (I, II, III, or IV), chemotherapy (yes or no), and radiotherapy (yes or no), and compared the expression levels of SEL1L/TUBA1C/SDC1 between them.